Biochemist Jennifer Doudna, a faculty scientist at the Department of Energy’s Lawrence Berkeley National Laboratory, founder of the Innovative Genomics Institute, and a professor at UC Berkeley, has ...
University of California, Berkeley biochemist Jennifer Doudna won the 2020 Nobel Prize in Chemistry alongside Emmanuelle Charpentier for their pioneering work on CRISPR-Cas9. This revolutionary genome ...
AZoLifeSciences on MSN
CRISPR for Christmas? The year’s biggest gene editing breakthroughs, unwrapped
In 2025, CRISPR advanced gene editing with safe, effective therapies and AI tools, marking a shift towards real-world ...
Victoria Gray, the first patient treated with CRISPR, and Jennifer Doudna, the CRISPR pioneer, at the 2025 Liberty Science Center's Genius Gala. In a recent conversation with Nobel Prize winning ...
In 2020, Jennifer Doudna, Ph.D., received the Nobel Prize in Chemistry, CRISPR-Cas9, a method for genome editing. Often referred to as “molecular scissors,” CRISPR cuts DNA at specific locations that ...
Explore how nanotechnology acts as the 'Convergence Engine' for AI materials discovery, CRISPR gene therapy delivery, and ...
Advances in the gene-editing technology known as CRISPR-Cas9 over the past 15 years have yielded important new insights into the roles that specific genes play in many diseases. But to date this ...
The American Chemical Society (ACS) is proud to announce that Jennifer A. Doudna is the recipient of the 2026 Priestley Medal. This award is the highest honor bestowed by ACS, and it annually ...
UCSF Benioff Children’s Hospital Oakland is enrolling patients in an innovative clinical trial that seeks to cure sickle cell disease. The trial is the first in the U.S. to apply non-viral CRISPR-Cas9 ...
CRISPR Therapeutics' Casgevy, the first CRISPR/Cas9 gene editing therapy, shows promising results in treating Sickle Cell Disease and beta thalassemia but faces challenges in patient adoption and cost ...
A new study in Nature Communications could influence how gene therapies are designed for many genetic diseases. Pictured: Gokul Ramadoss, the first author, is a PhD candidate in Bruce Conklin's lab at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback